{"blog": [], "keywords": [{"value": "Eli Lilly and Company", "name": "organizations", "rank": "1", "is_major": "N"}, {"value": "Johnson & Johnson", "name": "organizations", "rank": "2", "is_major": "N"}, {"value": "Abbott Laboratories", "name": "organizations", "rank": "3", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Medical Devices", "name": "subject", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/06/03/business/dealbook/johnson-johnson-is-urged-to-slim-down.html", "document_type": "article", "byline": {"person": [{"lastname": "CYRAN", "firstname": "Robert", "role": "reported", "organization": "", "rank": 1}], "original": "By ROBERT CYRAN"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "388", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "The health care giant is criticized by many investors for its mediocre shareholder returns and its lack of merger-and-acquisition activity.", "pub_date": "2016-06-03T00:00:00Z", "news_desk": "Business", "headline": {"kicker": "Breakingviews", "main": "Johnson &amp; Johnson Is Urged to Slim Down", "content_kicker": "Breakingviews"}, "print_page": null, "snippet": "The health care giant is criticized by many investors for its mediocre shareholder returns and its lack of merger-and-acquisition activity.", "_id": "57509af838f0d86ce33330ac", "slideshow_credits": null, "abstract": null}